Last reviewed · How we verify
Amotriphene (aminoxytriphene)
Amotriphene (generic name: aminoxytriphene) is a drug. It is currently in unknown development.
Amotriphene works by binding to specific proteins or receptors in the body to produce a therapeutic effect.
Amotriphene is a small molecule with selective binding to alpha-adrenergic receptors. It was developed as a coronary vasodilator in the early 1960s at Sterling Drug.
At a glance
| Generic name | aminoxytriphene |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like locks, and proteins or receptors are like keys. Amotriphene is like a key that fits into a specific lock, allowing it to turn and unlock a cellular process that helps to treat a particular disease or condition. This process can help to restore balance and normal function to the body's cells and tissues.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amotriphene CI brief — competitive landscape report
- Amotriphene updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Amotriphene
What is Amotriphene?
How does Amotriphene work?
What is the generic name of Amotriphene?
What development phase is Amotriphene in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing